- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Do | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Mi | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com | ||
| Mi | Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO | 1 | Seeking Alpha | ||
| Mi | Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm | 4 | Investing.com | ||
| Mi | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 131 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| Di | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Ikena Oncology ändert Vergütungsvereinbarung für Dr. Jotin Marango vor Fusion | 1 | Investing.com Deutsch | ||
| 15.07. | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 123 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen | |
| 12.07. | ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger | 5 | RTTNews | ||
| 11.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals | 77 | GlobeNewswire (Europe) | BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," the "Company") today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass... ► Artikel lesen | |
| 01.07. | Ikena Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.06. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 08.05. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 4 | SEC Filings | ||
| 21.04. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 18.03. | Ikena Oncology, Inc. - S-4, Registration of securities, business combinations | 4 | SEC Filings | ||
| 06.03. | Ikena Oncology, Inc. - 10-K, Annual Report | - | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,108 | +4,35 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| BIOGEN | 113,45 | +0,58 % | Biogen Inc.: ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression | CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,320 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| MAINZ BIOMED | 2,020 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und CARE schließen Kooperationsvereinbarung für gemeinsames Versorgungskonzept für Krankenkassen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,050 | +2,04 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity
Phase 2 VENTURE-Oral Dosing Trial Enrollment... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| ABIVAX | 58,50 | -1,68 % | Abivax: Phase 3 Erfolg bei Therapie für Colitis ulcerosa - Aktienkurs explodiert | Abivax hat mit seinem Wirkstoff Obefazimod in zwei globalen Phase 3 Induktionsstudien bedeutende Fortschritte bei der Behandlung von moderat bis schwer aktiver Colitis ulcerosa erzielt. Das französische... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,380 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 27,000 | +3,05 % | Galapagos NV: Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors | New Directors bring deep commercial, operational, and transaction experience to the Board
Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the... ► Artikel lesen | |
| CENTOGENE | 0,130 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,565 | +1,42 % | Cardiff Oncology vor Entscheidung: Die spannendste Krebs-Aktie! | Es ist der gewohnte Raketenstart nach Maß: Unser neuer Community-Tipp Cardiff Oncology legt furios los, gewinnt allein seit unserer Enthüllung im Live Chat vor genau einer Woche über 20% an Wert. Und... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,882 | +1,15 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 7,190 | 0,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,118 | +4,44 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| CYTOKINETICS | 31,800 | 0,00 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of... ► Artikel lesen |
IKENA ONCOLOGY INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKENA ONCOLOGY INC finden Sie auf Wallstreet Online.